Chongqing Dalin Biologic Technologies

Chongqing Dalin Biologic Technologies is a Chinese biopharmaceutical company specializing in the development and manufacture of plasma-based products. It operates as a subsidiary of China Biologic Products Holdings, Inc., which acquired a controlling interest in the company in 2009 to expand its footprint in the Chinese plasma market. Dalin's primary operational asset is its majority ownership in Guizhou Taibang Biological Products, one of the largest plasma-based biopharmaceutical producers in China. The company's commercial portfolio includes human albumin, intravenous immunoglobulin (IVIG), and specialized immunoglobulins for rabies, tetanus, and hepatitis B. Additionally, it produces critical coagulation factors such as Factor VIII and Prothrombin Complex Concentrate (PCC) for the treatment of hemophilia and other bleeding disorders.